



GILUPI extends Patent Portfolio - New US Patent granted

GILUPI GmbH announced today that the company was granted a US patent protecting the unique and innovative GILUPI technology for the capture of circulating cancer cells (CTCs) and further applications.

The US Patent and Trademark Office (USPTO) issued patent US10178966 entitled "Detection device for in-vivo and/or in-vitro enrichment of sample material". The patent describes a functionalized structured medical wire for the enrichment of sample material. The technology is already being used in clinical settings in Europe and China.

"Our products are currently not approved by the US FDA. With the issuance of this new US Patent we are further strengthening GILUPI's superior intellectual property position in the area of CTC enrichment. Furthermore, we create additional options to enter a new strategic market." commented Dr. Christian Jurinke, CEO of GILUPI GmbH.

GILUPI's patent portfolio consists of 11 patent families and further pending patent applications.

About GILUPI GmbH

GILUPI GmbH is a medical device company founded in 2006 with focus on the development and production of innovative products for the in vivo isolation of rare cells from the blood circulation. Currently, the main focus is the diagnostics market for cancer.

The concept of personalized medicine becomes increasingly important in oncology. The identification of the right drug for the individual patient is today's challenge in clinical practice. To address this medical need, the GILUPI CellCollector® is used to enrich rare cells by immuno-capture directly in the patient's bloodstream. This methodology has proven to yield highest cell numbers in various cancer types. Isolated cells can be characterized and analyzed down to a molecular level with immunostaining, DNA- or RNA-based methods.

The GILUPI CellCollector® is the first in vivo CTC isolation product that is CE approved.

For further information visit www.gilupi.com